Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience.

ABSTRACT:

Purpose

Several targeted agents demonstrated efficacy in early clinical trials for gastrointestinal (GI) cancers, but in many cases, phase-III trials and/or approval by the European Medicines Agency (EMA) are lacking. The primary focus of this study was to assess the regulatory processes associated with use and reimbursement of off-label treatment in precision oncology and to evaluate the benefit of targeted therapy in a real-world population in Germany.

Methods

Our cohort comprises 137 patients with GI cancers and is biased towards cancer entities with a high frequency of known targetable alterations, such as cholangiocarcinoma. Genetic testing was used to identify molecular targets, and therapy response was evaluated based on CT scans.

Results

A molecular target for

SUBMITTER: Welland S 

PROVIDER: S-EPMC9293869 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature